Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518884 | 0.95 | BACE1 (0.59) | BACE1NAALAD2GNPATMMEBACE2 | |
| SCHEMBL30312015 | 0.94 | BACE1 (0.65) | BACE1NAALAD2BACE2CTSD | |
| SCHEMBL30311968 | 0.94 | BACE1 (0.54) | BACE1NAALAD2MMEBACE2 | |
| SCHEMBL30312137 | 0.92 | BACE1 (0.64) | BACE1NAALAD2MMEBACE2CTSD | |
| SCHEMBL30312074 | 0.92 | BACE1 (0.55) | BACE1BACE2CTSD | |
| SCHEMBL31668884 | 0.90 | BACE1 (0.60) | BACE1NAALAD2MMEBACE2MMP1 | |
| SCHEMBL29630614 | 0.89 | BACE1 (0.53) | BACE1NAALAD2GNPATMME | |
| SCHEMBL29575905 | 0.89 | MME (0.55) | MME | |
| SCHEMBL31720970 | 0.88 | BACE1 (0.65) | BACE1NAALAD2BACE2CTSD | |
| SCHEMBL31005067 | 0.88 | BACE1 (0.70) | BACE1NAALAD2BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | ETH Zürich (CH) | 2026-02-24 | — | — | US | claimed |
| US-20230212228-A1 | Fibronectin-Binding Peptides for Use in Tumor or Fibrosis Diagnosis and Therapy | PAUL SCHERRER INSTITUT (CH) | 2023-07-06 | — | — | US | claimed |
| WO-2023057034-A1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH Zürich (CH) | 2023-04-13 | — | — | WO | claimed |
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | ETH Zürich (CH) | 2026-02-24 | — | — | US | disclosed |
| WO-2023057034-A1 | FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY | ETH Zürich (CH) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559525-B2 | Conjugated fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy | FN1, ASNS, FNIP1 | BACE1 2611/4885NAALAD2 292/4885GNPAT 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.